Sickle Cell and Red Cell Disorders Curative Therapy Center (CuRED) Clinical Studies

1 - 3 of 3

BMT CTN 1503 (STRIDE2): BMT for Severe Sickle Cell Disease

The purpose of this research study is to compare transplant (HCT/BMT) to standard of care treatment in young adults with SCD who have experienced complications. Once consented we would assess to see if you have a matched donor. Subjects who have a closely matched donor will undergo a bone marrow transplant. This is called the Donor Arm. Subjects who do not have a closely matched donor will receive the current standard of care for their disease. This is called the No Donor Arm. We will follow subjects in both arms for two years to evaluate outcomes over that time period. IRB 16-012854

HGB-212: Phase 3 Beta Thalassemia LentiGlobin BB305 Gene Therapy Trial

Individuals with a certain type of beta thalassemia that is treated with regular transfusions, and who are 50 years old and younger, may be able to participate. A number of screening tests will be done to determine if subjects can participate. These include review of your past medical history, blood and urine tests, bone marrow aspirate/biopsy, bone age/ DEXA scan, heart ultrasound, electrocardiogram, magnetic resonance imaging (MRI) of the heart and liver, and liver biopsy. If eligible, blood stem cells will be collected by apheresis or by bone marrow harvest. These stem cells will then have a healthy beta globin gene inserted. You will then be hospitalized and chemotherapy will be given to empty out the bone marrow. The stem cells, with the inserted gene, will then be given back to you. You will be followed for side effects and to see if the inserted gene helps you make hemoglobin.

A Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Subjects With Severe Sickle Cell Disease

The purpose of this research study is to learn more about the safety and effects of CTX001 (the “Study Product”) in patients ages 18 to 35 years who have been diagnosed with severe sickle cell disease. This is an open-label study in which subjects will receive one dose of the Study Product. The goal of is to see if a single “dose” of the Study Product allows the body to increase the amount of hemoglobin F (HbF) while decreasing the effects of SCD. CTX001, which is created by changing (editing) the DNA in the subjects blood stem cells near a gene called BCL11A